138 related articles for article (PubMed ID: 35253622)
1. MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.
Liao J; Chen H; Qi M; Wang J; Wang M
Cancer Biol Ther; 2022 Dec; 23(1):211-224. PubMed ID: 35253622
[TBL] [Abstract][Full Text] [Related]
2. MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
Zhang S; Wang M; Li Q; Zhu P
Cancer Biomark; 2017 Dec; 21(1):179-186. PubMed ID: 29081412
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
4. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Chen J; Zhao KN; Li R; Shao R; Chen C
Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
[TBL] [Abstract][Full Text] [Related]
5. Proteomic Analysis of Human Endometrial Tissues Reveals the Roles of PI3K/AKT/mTOR Pathway and Tumor Angiogenesis Molecules in the Pathogenesis of Endometrial Cancer.
Liu Z; Hong Z; Qu P
Biomed Res Int; 2020; 2020():5273969. PubMed ID: 32908897
[TBL] [Abstract][Full Text] [Related]
6. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
[TBL] [Abstract][Full Text] [Related]
7. SNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway.
Wu W; Chen X; Liu X; Bao HJ; Li QH; Xian JY; Lu BF; Zhao Y; Chen S
Mol Carcinog; 2023 Apr; 62(4):413-426. PubMed ID: 36562475
[TBL] [Abstract][Full Text] [Related]
8. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
10. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway.
Hou X; Zhao M; Wang T; Zhang G
Oncol Rep; 2014 Mar; 31(3):1175-82. PubMed ID: 24366110
[TBL] [Abstract][Full Text] [Related]
12. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.
Cipriano R; Miskimen KL; Bryson BL; Foy CR; Bartel CA; Jackson MW
Oncotarget; 2013 May; 4(5):729-38. PubMed ID: 23676467
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
14. HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway.
Zheng Y; Yang X; Wang C; Zhang S; Wang Z; Li M; Wang Y; Wang X; Yang X
Sci Rep; 2020 Feb; 10(1):3576. PubMed ID: 32107418
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA LINP1 functions as an oncogene in endometrial cancer progression by regulating the PI3K/AKT signaling pathway.
Zhang XH; Li M; Kang YJ; Xie YQ; Cao YX
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6830-6838. PubMed ID: 31486482
[TBL] [Abstract][Full Text] [Related]
16. LncRNA ENST00113 promotes proliferation, survival, and migration by activating PI3K/Akt/mTOR signaling pathway in atherosclerosis.
Yao X; Yan C; Zhang L; Li Y; Wan Q
Medicine (Baltimore); 2018 Apr; 97(16):e0473. PubMed ID: 29668625
[TBL] [Abstract][Full Text] [Related]
17. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
Zhang C; Yang N; Yang CH; Ding HS; Luo C; Zhang Y; Wu MJ; Zhang XW; Shen X; Jiang HL; Meng LH; Ding J
PLoS One; 2009; 4(3):e4881. PubMed ID: 19293927
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
Pavlidou A; Vlahos NF
ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
[TBL] [Abstract][Full Text] [Related]
19. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
